Michele Fornaro, Claudio Caiazza, Martina Billeci, Michael Berk, Wolfgang Marx, Vicent Balanzá-Martínez, Michele De Prisco, Rosanna Pezone, Giuseppe De Simone, Niccolo' Solini, Felice Iasevoli, Fabrice Berna, Guillaume Fond, Laurent Boyer, Andre F Carvalho, Elena Dragioti, Jess Fiedorowicz, Andrea de Bartolomeis, Christoph Correll, Marco Solmi
Background : Sub-optimal response in schizophrenia is frequent, warranting augmentation strategies over treatment-as-usual (TAU). Methods : We assessed nutraceuticals/phytoceutical augmentation strategies via network meta-analysis. Randomized controlled trials in schizophrenia/schizoaffective disorder were identified via the following databases: PubMed, MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL, and ClinicalTrials.gov. Change (Standardized Mean Difference=SMD) in total symptomatology and acceptability (Risk Ratio=RR) were co-primary outcomes...
January 12, 2024: Research Square